Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) Revenue (2019 - 2023)

Alx Oncology Holdings' Revenue history spans 4 years, with the latest figure at -$415000.0 for Q4 2023.

  • For Q4 2023, Revenue fell 79.65% year-over-year to -$415000.0; the TTM value through Dec 2023 reached -$1.6 million, down 557.56%, while the annual FY2025 figure was -$1.6 million, 7.35% up from the prior year.
  • Revenue for Q4 2023 was -$415000.0 at Alx Oncology Holdings, down from -$391000.0 in the prior quarter.
  • Across five years, Revenue topped out at $1.3 million in Q3 2019 and bottomed at -$415000.0 in Q4 2023.
  • The 4-year median for Revenue is -$2500.0 (2022), against an average of $154000.0.
  • The largest YoY upside for Revenue was 79.65% in 2023 against a maximum downside of 19450.0% in 2023.
  • A 4-year view of Revenue shows it stood at $1.2 million in 2019, then plummeted by 56.55% to $527000.0 in 2020, then crashed by 143.83% to -$231000.0 in 2022, then crashed by 79.65% to -$415000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Revenue are -$415000.0 (Q4 2023), -$391000.0 (Q3 2023), and -$372000.0 (Q2 2023).